Part 1 Basic Information

Name: Fengjie Jiang

Address: School of Pharmacy, Jiangsu University, No. 301 Xuefu Road, Zhenjiang, Jiangsu 212013, China

Email: 1000005793@ujs.edu.cn

Part 2 Personal Profile

Dr. Fengjie Jiang is a lecturer at the School of Pharmacy, Jiangsu University. Her research focuses on the regulatory mechanisms of epigenetic modifications (RNA methylation, histone modifications) in tumor initiation and progression, the discovery and mechanisms of action of targeted therapeutic drugs, mechanisms of tumor immune evasion and drug resistance, and exploration of combined immunotherapy and chemotherapy. The research findings were published in professional journals such as ‌J Hematol Oncol‌ and ‌J. Immunother. Cancer‌. She is a member of the Biochemical and Molecular Pharmacology Professional Committee of the Chinese Pharmacological Society.

Part 3 Education

•2018.09–2021.06, Nanjing University of Chinese Medicine, Major in Traditional Chinese Medicine‌, Ph.D.

•2011.09–2014.06, Guizhou Medical University, Major in Pharmaceutics, M.S.

•2007.09–2011.06, Guizhou Medical University, Major in Pharmacy, B.S.

Part 4 Work Experience

•2021.12–Present, School of Pharmacy, Jiangsu University, Lecturer.

Part 5 Research Interests

1.‌Study on the mechanisms of carcinogenesis and cancer evolution. Sequencing and omics technologies dissect the genetic, transcriptional, and epigenetic drivers of tumorigenesis; RNAi (interference) and overexpression techniques validate the functions of specific genes in tumor initiation and evolution at the cellular level. Using techniques such as co-immunoprecipitation (Co-IP) and ChIP-seq to dissect signaling pathway alterations and protein-protein/nucleic acid interaction networks in tumor cells.

2.Identification of tumor-specific targeted therapies. Integrating multi-omics data such as genomics, transcriptomics, proteomics, and metabolomics to comprehensively elucidate the molecular mechanisms of tumor initiation and progression, discover novel therapeutic targets and biomarkers, and screen targeted therapeutic drugs.

3.Research on Immune Evasion and Drug Resistance Mechanisms. Multiple omics technologies were employed to analyze tumor heterogeneity, the functional states of cell subpopulations, and key regulatory genes, identifying cell types and molecules associated with immune evasion and drug resistance.

Part 6 Research Achievements

6.1 Publications

1. Fengjie Jiang, Xiaozhu Tang, Chao Tang, et al. HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA [J]. Journal of Hematology & Oncology, 2021, 14:54.（SCI一区，IF=11.0）

2. Fengjie Jiang, Yu Shen, Bing Li, et al. Inhibition of histone demethylase LSD1 suppresses CD47 expression and enhances efficacy of CD47 blockade in breast cancer [J]. Journal for ImmunoTherapy of Cancer, 2026, 14(6): e014681.(SCI一区，IF=11.7）